Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Beware Intradialytic Hypotension: How Low Is Too Low?

Inrig JK.

Clin J Am Soc Nephrol. 2018 Oct 8;13(10):1453-1454. doi: 10.2215/CJN.10150818. Epub 2018 Sep 20. No abstract available.

PMID:
30237217
2.

Special situations: Intradialytic hypertension/chronic hypertension and intradialytic hypotension.

Van Buren PN, Inrig JK.

Semin Dial. 2017 Nov;30(6):545-552. doi: 10.1111/sdi.12631. Epub 2017 Jun 30. Review.

3.

Intradialytic hypotension, blood pressure changes and mortality risk in incident hemodialysis patients.

Chou JA, Streja E, Nguyen DV, Rhee CM, Obi Y, Inrig JK, Amin A, Kovesdy CP, Sim JJ, Kalantar-Zadeh K.

Nephrol Dial Transplant. 2018 Jan 1;33(1):149-159. doi: 10.1093/ndt/gfx037.

4.

Overcoming Barriers in Kidney Health-Forging a Platform for Innovation.

Linde PG, Archdeacon P, Breyer MD, Ibrahim T, Inrig JK, Kewalramani R, Lee CC, Neuland CY, Roy-Chaudhury P, Sloand JA, Meyer R, Smith KA, Snook J, West M, Falk RJ.

J Am Soc Nephrol. 2016 Jul;27(7):1902-10. doi: 10.1681/ASN.2015090976. Epub 2016 Apr 28.

5.

Mechanisms and Treatment of Intradialytic Hypertension.

Van Buren PN, Inrig JK.

Blood Purif. 2016;41(1-3):188-93. doi: 10.1159/000441313. Epub 2016 Jan 15. Review.

6.

Effect of low versus high dialysate sodium concentration on blood pressure and endothelial-derived vasoregulators during hemodialysis: a randomized crossover study.

Inrig JK, Molina C, D'Silva K, Kim C, Van Buren P, Allen JD, Toto R.

Am J Kidney Dis. 2015 Mar;65(3):464-73. doi: 10.1053/j.ajkd.2014.10.021. Epub 2014 Dec 17.

PMID:
25530107
7.

The landscape of clinical trials in nephrology: a systematic review of Clinicaltrials.gov.

Inrig JK, Califf RM, Tasneem A, Vegunta RK, Molina C, Stanifer JW, Chiswell K, Patel UD.

Am J Kidney Dis. 2014 May;63(5):771-80. doi: 10.1053/j.ajkd.2013.10.043. Epub 2013 Dec 6. Review.

8.

Peri-dialytic hypertension and hypotension: another U-shaped BP-outcome association.

Inrig JK.

Kidney Int. 2013 Oct;84(4):641-4. doi: 10.1038/ki.2013.247.

9.

Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease.

McCullough PA, Barnhart HX, Inrig JK, Reddan D, Sapp S, Patel UD, Singh AK, Szczech LA, Califf RM.

Am J Nephrol. 2013;37(6):549-58. doi: 10.1159/000351175. Epub 2013 May 25.

10.

Association of intradialytic blood pressure variability with increased all-cause and cardiovascular mortality in patients treated with long-term hemodialysis.

Flythe JE, Inrig JK, Shafi T, Chang TI, Cape K, Dinesh K, Kunaparaju S, Brunelli SM.

Am J Kidney Dis. 2013 Jun;61(6):966-74. doi: 10.1053/j.ajkd.2012.12.023. Epub 2013 Mar 6.

11.

The prevalence of persistent intradialytic hypertension in a hemodialysis population with extended follow-up.

Van Buren PN, Kim C, Toto RD, Inrig JK.

Int J Artif Organs. 2012 Dec;35(12):1031-8. doi: 10.5301/ijao.5000126.

PMID:
23065874
12.

Probing the mechanisms of intradialytic hypertension: a pilot study targeting endothelial cell dysfunction.

Inrig JK, Van Buren P, Kim C, Vongpatanasin W, Povsic TJ, Toto R.

Clin J Am Soc Nephrol. 2012 Aug;7(8):1300-9. doi: 10.2215/CJN.10010911. Epub 2012 Jun 14.

13.

Impact of higher hemoglobin targets on blood pressure and clinical outcomes: a secondary analysis of CHOIR.

Inrig JK, Sapp S, Barnhart H, Patel UD, Reddan D, Singh A, Califf RM, Szczech L.

Nephrol Dial Transplant. 2012 Sep;27(9):3606-14. doi: 10.1093/ndt/gfs123. Epub 2012 May 9.

14.

Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial.

Inrig JK, Barnhart HX, Reddan D, Patel UD, Sapp S, Califf RM, Singh AK, Szczech LA.

Am J Kidney Dis. 2012 Sep;60(3):390-401. doi: 10.1053/j.ajkd.2012.03.009. Epub 2012 Apr 25.

15.

New perspectives on blood pressure variability in hemodialysis patients.

Van Buren PN, Shastri S, Inrig JK.

Am J Kidney Dis. 2012 Mar;59(3):333-5. doi: 10.1053/j.ajkd.2012.01.003. No abstract available.

PMID:
22340909
16.

Association between high-dose erythropoiesis-stimulating agents, inflammatory biomarkers, and soluble erythropoietin receptors.

Inrig JK, Bryskin SK, Patel UD, Arcasoy M, Szczech LA.

BMC Nephrol. 2011 Dec 12;12:67. doi: 10.1186/1471-2369-12-67.

17.

Interdialytic ambulatory blood pressure in patients with intradialytic hypertension.

Van Buren PN, Toto R, Inrig JK.

Curr Opin Nephrol Hypertens. 2012 Jan;21(1):15-23. doi: 10.1097/MNH.0b013e32834db3e4. Review.

18.

Veterans more likely to start hemodialysis with an arteriovenous fistula.

Parikh DS, Inrig JK, Kipp A, Szczech LA, McClellan W, Patel UD.

Semin Dial. 2011 Sep-Oct;24(5):570-5. doi: 10.1111/j.1525-139X.2011.00920.x. Epub 2011 Sep 13.

PMID:
21913987
19.

Blood pressure management.

Inrig JK.

Semin Dial. 2011 Sep-Oct;24(5):512-4. doi: 10.1111/j.1525-139X.2011.00958.x. Epub 2011 Aug 28. No abstract available.

PMID:
21883468
20.

Intradialytic hypertension and its association with endothelial cell dysfunction.

Inrig JK, Van Buren P, Kim C, Vongpatanasin W, Povsic TJ, Toto RD.

Clin J Am Soc Nephrol. 2011 Aug;6(8):2016-24. doi: 10.2215/CJN.11351210. Epub 2011 Jul 14.

21.

Intradialytic hypertension and the association with interdialytic ambulatory blood pressure.

Van Buren PN, Kim C, Toto R, Inrig JK.

Clin J Am Soc Nephrol. 2011 Jul;6(7):1684-91. doi: 10.2215/CJN.11041210.

22.

Differential outcomes between dialysis modalities: purely a reflection of selection bias?

Inrig JK, Toto RD.

J Am Soc Nephrol. 2011 Jun;22(6):989-90. doi: 10.1681/ASN.2011040394. No abstract available.

23.

Hypertension and hemodialysis: pathophysiology and outcomes in adult and pediatric populations.

Van Buren PN, Inrig JK.

Pediatr Nephrol. 2012 Mar;27(3):339-50. doi: 10.1007/s00467-011-1775-3. Epub 2011 Feb 1. Review.

24.

ASN End-Stage Renal Disease Task Force: perspective on prospective payments for renal dialysis facilities.

Sedor JR, Watnick S, Patel UD, Cheung A, Harmon W, Himmelfarb J, Hostetter TH, Inrig JK, Mehrotra R, Robinson E, Smedberg PC, Shaffer RN; American Society of Nephrology ESRD Task Force.

J Am Soc Nephrol. 2010 Aug;21(8):1235-7. doi: 10.1681/ASN.2010060656. Epub 2010 Jul 22. No abstract available.

25.

Antihypertensive agents in hemodialysis patients: a current perspective.

Inrig JK.

Semin Dial. 2010 May-Jun;23(3):290-7. doi: 10.1111/j.1525-139X.2009.00697.x. Epub 2010 Mar 29. Review.

26.

Perioperative outcomes among patients with end-stage renal disease following coronary artery bypass surgery in the USA.

Parikh DS, Swaminathan M, Archer LE, Inrig JK, Szczech LA, Shaw AD, Patel UD.

Nephrol Dial Transplant. 2010 Jul;25(7):2275-83. doi: 10.1093/ndt/gfp781. Epub 2010 Jan 26.

27.

A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment.

Szczech LA, Barnhart HX, Sapp S, Felker GM, Hernandez A, Reddan D, Califf RM, Inrig JK, Patel UD, Singh AK.

Kidney Int. 2010 Feb;77(3):239-46. doi: 10.1038/ki.2009.415. Epub 2009 Nov 4.

28.

Intradialytic hypertension: a less-recognized cardiovascular complication of hemodialysis.

Inrig JK.

Am J Kidney Dis. 2010 Mar;55(3):580-9. doi: 10.1053/j.ajkd.2009.08.013. Epub 2009 Oct 22. Review.

29.

Is choice of antihypertensive agent important in improving cardiovascular outcomes in high-risk hypertensive patients?

Inrig JK, Toto RD.

Am J Kidney Dis. 2009 Dec;54(6):1000-4. doi: 10.1053/j.ajkd.2009.08.003. Epub 2009 Sep 25. No abstract available.

30.

Decreased pulse pressure during hemodialysis is associated with improved 6-month outcomes.

Inrig JK, Patel UD, Toto RD, Reddan DN, Himmelfarb J, Lindsay RM, Stivelman J, Winchester JF, Szczech LA.

Kidney Int. 2009 Nov;76(10):1098-107. doi: 10.1038/ki.2009.340. Epub 2009 Sep 2.

31.
32.

Outcomes of Staphylococcus aureus infection in hemodialysis-dependent patients.

Li Y, Friedman JY, O'Neal BF, Hohenboken MJ, Griffiths RI, Stryjewski ME, Middleton JP, Schulman KA, Inrig JK, Fowler VG Jr, Reed SD.

Clin J Am Soc Nephrol. 2009 Feb;4(2):428-34. doi: 10.2215/CJN.03760708. Epub 2008 Dec 31.

33.

Chronic kidney disease after hematopoietic cell transplantation: a systematic review.

Ellis MJ, Parikh CR, Inrig JK, Kanbay M, Patel UD.

Am J Transplant. 2008 Nov;8(11):2378-90. doi: 10.1111/j.1600-6143.2008.02408.x. Review. Erratum in: Am J Transplant. 2009 Apr;9(4):865. Kambay, M [corrected to Kanbay, M].

34.

Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes.

Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, Patel UD, Singh AK.

Kidney Int. 2008 Sep;74(6):791-8. doi: 10.1038/ki.2008.295. Epub 2008 Jul 2.

35.

Negative trials in nephrology: what can we learn?

Novak JE, Inrig JK, Patel UD, Califf RM, Szczech LA.

Kidney Int. 2008 Nov;74(9):1121-7. doi: 10.1038/ki.2008.286. Epub 2008 Jun 18. Review.

36.

Mortality, kidney disease and cardiac procedures following acute coronary syndrome.

Inrig JK, Patel UD, Briley LP, She L, Gillespie BS, Easton JD, Topol EJ, Szczech LA.

Nephrol Dial Transplant. 2008 Mar;23(3):934-40. Epub 2007 Nov 4.

PMID:
17984102
37.

Risk for cardiovascular outcomes among subjects with atherosclerotic cardiovascular disease and greater-than-normal estimated glomerular filtration rate.

Inrig JK, Gillespie BS, Patel UD, Briley LP, She L, Easton JD, Topol E, Szczech LA.

Clin J Am Soc Nephrol. 2007 Nov;2(6):1215-22. Epub 2007 Oct 17.

38.

Mortality by dialysis modality among patients who have end-stage renal disease and are awaiting renal transplantation.

Inrig JK, Sun JL, Yang Q, Briley LP, Szczech LA.

Clin J Am Soc Nephrol. 2006 Jul;1(4):774-9. Epub 2006 May 3.

39.

Relationship between clinical outcomes and vascular access type among hemodialysis patients with Staphylococcus aureus bacteremia.

Inrig JK, Reed SD, Szczech LA, Engemann JJ, Friedman JY, Corey GR, Schulman KA, Reller LB, Fowler VG Jr.

Clin J Am Soc Nephrol. 2006 May;1(3):518-24. Epub 2006 Mar 22.

40.

Relationship between interdialytic weight gain and blood pressure among prevalent hemodialysis patients.

Inrig JK, Patel UD, Gillespie BS, Hasselblad V, Himmelfarb J, Reddan D, Lindsay RM, Winchester JF, Stivelman J, Toto R, Szczech LA.

Am J Kidney Dis. 2007 Jul;50(1):108-18, 118.e1-4.

41.

Anemia management in chronic kidney disease.

Gillespie BS, Inrig JK, Szczech LA.

Hemodial Int. 2007 Jan;11(1):15-20. Review.

PMID:
17257350
42.

Association of intradialytic blood pressure changes with hospitalization and mortality rates in prevalent ESRD patients.

Inrig JK, Oddone EZ, Hasselblad V, Gillespie B, Patel UD, Reddan D, Toto R, Himmelfarb J, Winchester JF, Stivelman J, Lindsay RM, Szczech LA.

Kidney Int. 2007 Mar;71(5):454-61. Epub 2007 Jan 10.

43.

Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia.

Stryjewski ME, Szczech LA, Benjamin DK Jr, Inrig JK, Kanafani ZA, Engemann JJ, Chu VH, Joyce MJ, Reller LB, Corey GR, Fowler VG Jr.

Clin Infect Dis. 2007 Jan 15;44(2):190-6. Epub 2006 Dec 8.

PMID:
17173215

Supplemental Content

Loading ...
Support Center